June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Targeting Notch signaling as a novel therapy for Retinoblastoma
Author Affiliations & Notes
  • Laura Asnaghi
    Neuropathology, Johns Hopkins University, Baltimore, MD
  • Arushi Tripathy
    Neuropathology, Johns Hopkins University, Baltimore, MD
  • Charles Eberhart
    Neuropathology, Johns Hopkins University, Baltimore, MD
    Ophthalmology, Johns Hopkins University, Baltimore, MD
  • Footnotes
    Commercial Relationships Laura Asnaghi, None; Arushi Tripathy, None; Charles Eberhart, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 1662. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Laura Asnaghi, Arushi Tripathy, Charles Eberhart; Targeting Notch signaling as a novel therapy for Retinoblastoma. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1662.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Retinoblastoma, a malignant tumor of the retina, is the most common intraocular cancer of childhood. Our goal was to study the role of Notch signaling in promoting growth and proliferation of retinoblastoma cells to determine if inhibiting this pathway might represent a novel approach to treatment.

Methods: WERI Rb1 and Y79 retinoblastoma lines were used as model. Expression of Notch pathway components was measured using qPCR and Western blot. Downregulation of the Jag2 ligand was achieved using short hairpin RNA (shRNA). Cell growth, proliferation, and invasion of these cell lines, upon downregulation of Jag2, were determined respectively using the colorimetric CCK8 (Cell Counting kit‑8) assay, bromodeoxyuridine incorporation and transwell invasion assays.

Results: We found that Notch pathway components, including Jag1-2 ligands, Notch receptors and Hes1, Hey1-2 target genes, were expressed at various levels in WERI Rb1 and Y79 retinoblastoma lines. Notch ligand Jag2 RNA and protein were more highly expressed as compared to Jag1 in the retinoblastoma lines. Notch1 receptor was found to be more abundantly expressed than Notch2 and Notch3 receptors in these lines. The cleaved, active form of Notch1 was detected under standard culture conditions, further supporting a potential role for the pathway in retinoblastoma. Because Jag2 was highly expressed, we performed loss-of-function studies using shRNA. Downregulation of Jag2 significantly suppressed cell growth and proliferation by 40 to 50% in both lines, as determined respectively by CCK8 and bromodeoxyuridine assays, and partially reduced invasion, as found by transwell invasion assay.

Conclusions: Our findings indicate that Notch pathway components are expressed in WERI Rb1 and Y79 retinoblastoma lines, with the presence of cleaved Notch1 receptor and downstream targets further supporting pathway activity. Jag2 ligand appeared to be highly expressed and promoted retinoblastoma growth. These data suggest that Notch inhibitors represent a new potential therapeutic strategy in retinoblastoma.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×